Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 6/20 | 0.65 |
| ▸ | CDK2 | P24941 | 6/20 | 0.51 |
| ▸ | CDK4 | P11802 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.47 |
| ▸ | CDK9 | P50750 | 7/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL4877880 | 0.96 | IKBKB (0.60) | IKBKBCDK2CDK4CDK1CCNT1 | |
| SCHEMBL3515574 | 0.95 | IKBKB (0.64) | IKBKBCDK2CDK4CDK1CCNT1 | |
| SCHEMBL3516415 | 0.91 | IKBKB (0.59) | IKBKBCDK2CDK4CDK1CCNT1 | |
| SCHEMBL3517971 | 0.91 | IKBKB (0.53) | IKBKBCDK2CDK1CDK9 | |
| SCHEMBL4880084 | 0.90 | IKBKB (0.63) | IKBKBCDK2CDK4CDK1CCNT1 | |
| SCHEMBL4872194 | 0.89 | IKBKB (0.62) | IKBKBCDK2CDK4CDK1CCNT1 | |
| SCHEMBL3516442 | 0.88 | CDK2 (0.57) | IKBKBCDK2CDK4CCNT1CDK9 | |
| SCHEMBL3521164 | 0.88 | IKBKB (0.67) | IKBKBCDK2CDK4CDK1 | |
| SCHEMBL3521723 | 0.88 | IKBKB (0.50) | IKBKBCDK2CDK4CDK1CCNT1 | |
| SCHEMBL3521501 | 0.88 | IKBKB (0.50) | IKBKBCDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | claimed |
| US-20080275073-A1 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS | WYETH (US) | 2008-11-06 | — | — | US | claimed |
| US-20080262009-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS ACETATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | claimed |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | WYETH (US) | 2008-10-23 | — | — | US | claimed |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | claimed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080275073-A1 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS | WYETH (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080275073-A1 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS | WYETH (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080275073-A1 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS | WYETH (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080262009-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS ACETATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262009-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS ACETATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262009-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS ACETATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275073-A1 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS | ABCG2, CYP3A43, CYP2D6 | IKBKB 4165/4885CDK2 806/4885CDK4 1315/4885 |
| US-20080262009-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS ACETATE SALTS | CYP2F1, CYP4B1, CYP3A4 | IKBKB 4538/4885CDK2 188/4885CDK4 294/4885 |
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | IKBKB 3246/4885CDK2 11/4885CDK4 69/4885 |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | GALE, UGGT1, UGT1A3 | IKBKB 4349/4885CDK2 660/4885CDK4 514/4885 |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | CSNK1A1, PRKX, PRKACA | IKBKB 327/4885CDK2 123/4885CDK4 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.